Importantly, the use of SGLT-2 inhibitors was associated with increased risks of DKA compared to a placebo in the CREDENCE and SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) studies, while this was not observed in DAPA-CKD and EMPA-KIDNEY. The gene discussed is SLC5A2; the disease is chronic kidney disease.